May 9 |
Avidity Biosciences GAAP EPS of -$0.79 beats by $0.07, revenue of $3.54M beats by $0.97M
|
May 9 |
Avidity Biosciences files automatic mixed shelf
|
May 9 |
Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
|
May 8 |
Avidity gets FDA breakthrough therapy status for DM1 drug
|
May 8 |
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1
|
May 3 |
BofA starts Avidity at buy, cites upcoming clinical data
|
Apr 18 |
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
|